secwatch.observer — SEC 8-K summary
======================================

Issuer:     OptimizeRx Corp (OPRX)
CIK:        0001448431
Form:       8-K
Filed at:   2025-08-07T23:59:59+00:00
Accession:  0001448431-25-000010
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

OptimizeRx Q2 revenue $29.2M (+55% YoY); raises FY guidance to $104M-$108M
--------------------------------------------------------------------------

- Q2 GAAP net income $1.5M ($0.08/share) vs net loss of $4.0M ($0.22) YoY.
- Adjusted EBITDA $5.8M vs $0.5M YoY; non-GAAP net income $4.5M ($0.24 diluted).
- Q2 gross profit $18.6M, up 59% YoY; revenue growth driven by deeper pharma partnerships.
- Paid down $4.5M of principal on term loan during Q2, $4.0M above required schedule.
- FY 2025 guidance raised: revenue $104M-$108M, adjusted EBITDA $14.5M-$17.5M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1448431/000144843125000010/0001448431-25-000010-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1448431/000144843125000010/oprx-20250807.htm
  HTML page:      https://secwatch.observer/filing/0001448431-25-000010

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer